Adverse Event reporting information can be found in footer
Request a Meeting
“There is a suggestion in some studies and a SR and meta-analysis that cardiovascular side effects are less frequent in patients treated with LHRH antagonists than patients treated with LHRH agonists therefore patients with pre-existing cardiovascular disease or other cardiovascular risk factors might be considered to be treated with antagonists if a chemical castration is chosen”.
Use of a GnRH antagonist may be considered in men with a prior history of myocardial infarction or stroke, or with significant cardiac comorbidities
“It might be time to consider treating men who have pre-existing CV risk factors with a GnRH antagonist rather than an agonist.’’ 14
Adapted from Davey P and Alexandrou P. 202210
References
1. Albertsen PC, et al. Eur Urol 2014;65:565-573.
2. Davey P and Kirby MG. World J Urol 2021;39:307-315.
3. Margel D, et al. J Urol 2019;202(6):1199–1208.
4. Perrone V, et al. Ther Clin Risk Manag 2020;16:393–401.
5. Cone EB, et al. J Clin Oncol 2020;38:6 Suppl 34.
6. Health Matters: Preventing cardiovascular disease. UK Health Security Agency. Available at: https://ukhsa.blog.gov.uk/2019/02/14/health-matters-preventing-cardiovascular-disease/. Last accessed: January 2024.
7. British Heart Foundation. Heart statistics. Available at: https://www.bhf.org.uk/what-we-do/our-research/heart-statistics. Last accessed: January 2024.
8. Hospital Episode Statistics (HES) database. (Data for Jan-Dec 2021).
9. Cereda V, et al. Heart Fail Rev 2022;27:119–134.
10. Davey P and Alexandrou K. Int J Clin Pract 2022; https://doi.org/10.1155/2022/2976811.
11. Kenk M, et al. Can Urol Assoc J 2020;14:E458–E464.
12. Cornford P, et al. European Association of Urology. Prostate cancer guidelines. Available at: uroweb.org/guideline/prostate-cancer/. Last accessed: February 2024.
13. Kokorovic A, et al. Can Urol Assoc J 2021;15:E307–E322.
14. Higano CS, et al. N Engl J Med 2020;382:2257–2259.
15. Zhang KW, et al. J Urol 2021;206(3):613-622
Job Code: UK-FN-2400004 - Date of Preparation: March 2024